Modulation of doxorubicin sensitivity by a novel organic compound, oxalyl bis ( N-phenyl) hydroxamic acid on acetyl aminofluorene-induced preneoplastic hepatocytes
Development of biochemical modulators and application of the same with anticancer drugs is a current approach of modern cancer chemotherapy. We report the effect of two novel hydroxamic acid derivatives, viz. oxaly bis ( N-phenyl) hydroxamic acid (OBPHA) and succinyl bis ( N-phenyl) hydroxamic acid...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2003-12, Vol.202 (1), p.25-34 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 34 |
|---|---|
| container_issue | 1 |
| container_start_page | 25 |
| container_title | Cancer letters |
| container_volume | 202 |
| creator | Choudhuri, S.K Majumder, Surajit |
| description | Development of biochemical modulators and application of the same with anticancer drugs is a current approach of modern cancer chemotherapy. We report the effect of two novel hydroxamic acid derivatives, viz. oxaly bis (
N-phenyl) hydroxamic acid (OBPHA) and succinyl bis (
N-phenyl) hydroxamic acid (SBPHA) on doxorubicin sensitivity and on P-glycoprotein (P-gp) in acetyl amino fluorene (AAF) induced preneoplastic hepatocytes in vitro. OBPHA increases doxorubicin sensitivity in AAF induced preneoplastic hepatocytes compared to normal hepatocytes. SBPHA, with an additional –CH
2–CH
2– group than OBPHA does not modulate the sensitivity of doxorubicin. The mechanism of action of OBPHA and SBPHA and their in vivo toxicity on male Swiss mice has been studied. OBPHA in combination with doxorubicin (i.e. OBPHA+doxorubicin) has higher antitumour activity compared to doxorubicin alone group; in consequence, OBPHA may decrease the dose related side effect of doxorubicin. |
| doi_str_mv | 10.1016/S0304-3835(03)00474-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1505365658</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304383503004749</els_id><sourcerecordid>3241505631</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-ce7106796e7d37aa463fc86b3e6f1de9958cf6e8528f494da0e4ab7c7c47a0df3</originalsourceid><addsrcrecordid>eNqFkd9qFDEUxoModq0-ghIQoQVHk82_mSuR0qpQ9UK9DpnkxE2ZTabJzNJ5Hl_UbHexl16Fk_P7zjl8H0IvKXlHCZXvfxBGeMNaJs4IOyeEK950j9CKtmrdqK4lj9HqH3KCnpVyQwgRXImn6IRyyRlZsxX68zW5eTBTSBEnj126S3nugw0RF4glTGEXpgX3CzY4ph0MOOXfJgaLbdqOaY7uLU53ZlgG3IeCz_C3ZtxAXIZzvFlcrq1tZY0NDtcNxsJUyfoXkx_mlCFCE6KbLTg87qs0DqZMVbKB0UzJLhOU5-iJN0OBF8f3FP26uvx58bm5_v7py8XH68Zy2k2NBUWJVJ0E5ZgyhkvmbSt7BtJTB10nWusltGLdet5xZwhw0yurLFeGOM9O0evD3DGn2xnKpG_SnGNdqakggkkhRVspcaBsTqVk8HrMYWvyoinR-2j0fTR677smTN9Ho7uqe3WcPvdbcA-qYxYVeHMETLFm8NlEG8oDJxhRVNHKfThwUL3YBci62ACxWhgy2Em7FP5zyl9JBa7w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1505365658</pqid></control><display><type>article</type><title>Modulation of doxorubicin sensitivity by a novel organic compound, oxalyl bis ( N-phenyl) hydroxamic acid on acetyl aminofluorene-induced preneoplastic hepatocytes</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Choudhuri, S.K ; Majumder, Surajit</creator><creatorcontrib>Choudhuri, S.K ; Majumder, Surajit</creatorcontrib><description>Development of biochemical modulators and application of the same with anticancer drugs is a current approach of modern cancer chemotherapy. We report the effect of two novel hydroxamic acid derivatives, viz. oxaly bis (
N-phenyl) hydroxamic acid (OBPHA) and succinyl bis (
N-phenyl) hydroxamic acid (SBPHA) on doxorubicin sensitivity and on P-glycoprotein (P-gp) in acetyl amino fluorene (AAF) induced preneoplastic hepatocytes in vitro. OBPHA increases doxorubicin sensitivity in AAF induced preneoplastic hepatocytes compared to normal hepatocytes. SBPHA, with an additional –CH
2–CH
2– group than OBPHA does not modulate the sensitivity of doxorubicin. The mechanism of action of OBPHA and SBPHA and their in vivo toxicity on male Swiss mice has been studied. OBPHA in combination with doxorubicin (i.e. OBPHA+doxorubicin) has higher antitumour activity compared to doxorubicin alone group; in consequence, OBPHA may decrease the dose related side effect of doxorubicin.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/S0304-3835(03)00474-9</identifier><identifier>PMID: 14643023</identifier><identifier>CODEN: CALEDQ</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>2-Acetylaminofluorene - toxicity ; Acids ; Animals ; Antibiotics, Antineoplastic - therapeutic use ; Antineoplastic agents ; ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism ; Benzeneacetamides - therapeutic use ; Biological and medical sciences ; Bone marrow ; Calcium Channel Blockers - pharmacology ; Carcinogens ; Carcinogens - toxicity ; Cell Division - drug effects ; Dose-Response Relationship, Drug ; Doxorubicin (Dox) ; Doxorubicin - therapeutic use ; Drug dosages ; Drug Synergism ; Drug Therapy, Combination ; Experiments ; Glutathione - metabolism ; Hepatocytes - drug effects ; Hepatocytes - metabolism ; Hepatocytes - pathology ; Humans ; Hydroxamic Acids - therapeutic use ; Male ; Medical sciences ; Methods ; Mice ; Modulators ; Oxalates - therapeutic use ; Oxalyl bis ( N-phenyl) hydroxamic acid (OBPHA) ; Pharmacology. Drug treatments ; Precancerous Conditions - chemically induced ; Precancerous Conditions - drug therapy ; Precancerous Conditions - metabolism ; Rats ; Rats, Sprague-Dawley ; Rodents ; Sensitivity ; Spleen - metabolism ; Survival Rate ; Tumor Cells, Cultured ; Tumors ; Verapamil - pharmacology</subject><ispartof>Cancer letters, 2003-12, Vol.202 (1), p.25-34</ispartof><rights>2003 Elsevier Ireland Ltd</rights><rights>2004 INIST-CNRS</rights><rights>Copyright Elsevier Limited Dec 8, 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-ce7106796e7d37aa463fc86b3e6f1de9958cf6e8528f494da0e4ab7c7c47a0df3</citedby><cites>FETCH-LOGICAL-c419t-ce7106796e7d37aa463fc86b3e6f1de9958cf6e8528f494da0e4ab7c7c47a0df3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0304-3835(03)00474-9$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15307171$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14643023$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Choudhuri, S.K</creatorcontrib><creatorcontrib>Majumder, Surajit</creatorcontrib><title>Modulation of doxorubicin sensitivity by a novel organic compound, oxalyl bis ( N-phenyl) hydroxamic acid on acetyl aminofluorene-induced preneoplastic hepatocytes</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Development of biochemical modulators and application of the same with anticancer drugs is a current approach of modern cancer chemotherapy. We report the effect of two novel hydroxamic acid derivatives, viz. oxaly bis (
N-phenyl) hydroxamic acid (OBPHA) and succinyl bis (
N-phenyl) hydroxamic acid (SBPHA) on doxorubicin sensitivity and on P-glycoprotein (P-gp) in acetyl amino fluorene (AAF) induced preneoplastic hepatocytes in vitro. OBPHA increases doxorubicin sensitivity in AAF induced preneoplastic hepatocytes compared to normal hepatocytes. SBPHA, with an additional –CH
2–CH
2– group than OBPHA does not modulate the sensitivity of doxorubicin. The mechanism of action of OBPHA and SBPHA and their in vivo toxicity on male Swiss mice has been studied. OBPHA in combination with doxorubicin (i.e. OBPHA+doxorubicin) has higher antitumour activity compared to doxorubicin alone group; in consequence, OBPHA may decrease the dose related side effect of doxorubicin.</description><subject>2-Acetylaminofluorene - toxicity</subject><subject>Acids</subject><subject>Animals</subject><subject>Antibiotics, Antineoplastic - therapeutic use</subject><subject>Antineoplastic agents</subject><subject>ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism</subject><subject>Benzeneacetamides - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bone marrow</subject><subject>Calcium Channel Blockers - pharmacology</subject><subject>Carcinogens</subject><subject>Carcinogens - toxicity</subject><subject>Cell Division - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Doxorubicin (Dox)</subject><subject>Doxorubicin - therapeutic use</subject><subject>Drug dosages</subject><subject>Drug Synergism</subject><subject>Drug Therapy, Combination</subject><subject>Experiments</subject><subject>Glutathione - metabolism</subject><subject>Hepatocytes - drug effects</subject><subject>Hepatocytes - metabolism</subject><subject>Hepatocytes - pathology</subject><subject>Humans</subject><subject>Hydroxamic Acids - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methods</subject><subject>Mice</subject><subject>Modulators</subject><subject>Oxalates - therapeutic use</subject><subject>Oxalyl bis ( N-phenyl) hydroxamic acid (OBPHA)</subject><subject>Pharmacology. Drug treatments</subject><subject>Precancerous Conditions - chemically induced</subject><subject>Precancerous Conditions - drug therapy</subject><subject>Precancerous Conditions - metabolism</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Rodents</subject><subject>Sensitivity</subject><subject>Spleen - metabolism</subject><subject>Survival Rate</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors</subject><subject>Verapamil - pharmacology</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkd9qFDEUxoModq0-ghIQoQVHk82_mSuR0qpQ9UK9DpnkxE2ZTabJzNJ5Hl_UbHexl16Fk_P7zjl8H0IvKXlHCZXvfxBGeMNaJs4IOyeEK950j9CKtmrdqK4lj9HqH3KCnpVyQwgRXImn6IRyyRlZsxX68zW5eTBTSBEnj126S3nugw0RF4glTGEXpgX3CzY4ph0MOOXfJgaLbdqOaY7uLU53ZlgG3IeCz_C3ZtxAXIZzvFlcrq1tZY0NDtcNxsJUyfoXkx_mlCFCE6KbLTg87qs0DqZMVbKB0UzJLhOU5-iJN0OBF8f3FP26uvx58bm5_v7py8XH68Zy2k2NBUWJVJ0E5ZgyhkvmbSt7BtJTB10nWusltGLdet5xZwhw0yurLFeGOM9O0evD3DGn2xnKpG_SnGNdqakggkkhRVspcaBsTqVk8HrMYWvyoinR-2j0fTR677smTN9Ho7uqe3WcPvdbcA-qYxYVeHMETLFm8NlEG8oDJxhRVNHKfThwUL3YBci62ACxWhgy2Em7FP5zyl9JBa7w</recordid><startdate>20031208</startdate><enddate>20031208</enddate><creator>Choudhuri, S.K</creator><creator>Majumder, Surajit</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20031208</creationdate><title>Modulation of doxorubicin sensitivity by a novel organic compound, oxalyl bis ( N-phenyl) hydroxamic acid on acetyl aminofluorene-induced preneoplastic hepatocytes</title><author>Choudhuri, S.K ; Majumder, Surajit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-ce7106796e7d37aa463fc86b3e6f1de9958cf6e8528f494da0e4ab7c7c47a0df3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>2-Acetylaminofluorene - toxicity</topic><topic>Acids</topic><topic>Animals</topic><topic>Antibiotics, Antineoplastic - therapeutic use</topic><topic>Antineoplastic agents</topic><topic>ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism</topic><topic>Benzeneacetamides - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bone marrow</topic><topic>Calcium Channel Blockers - pharmacology</topic><topic>Carcinogens</topic><topic>Carcinogens - toxicity</topic><topic>Cell Division - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Doxorubicin (Dox)</topic><topic>Doxorubicin - therapeutic use</topic><topic>Drug dosages</topic><topic>Drug Synergism</topic><topic>Drug Therapy, Combination</topic><topic>Experiments</topic><topic>Glutathione - metabolism</topic><topic>Hepatocytes - drug effects</topic><topic>Hepatocytes - metabolism</topic><topic>Hepatocytes - pathology</topic><topic>Humans</topic><topic>Hydroxamic Acids - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methods</topic><topic>Mice</topic><topic>Modulators</topic><topic>Oxalates - therapeutic use</topic><topic>Oxalyl bis ( N-phenyl) hydroxamic acid (OBPHA)</topic><topic>Pharmacology. Drug treatments</topic><topic>Precancerous Conditions - chemically induced</topic><topic>Precancerous Conditions - drug therapy</topic><topic>Precancerous Conditions - metabolism</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Rodents</topic><topic>Sensitivity</topic><topic>Spleen - metabolism</topic><topic>Survival Rate</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors</topic><topic>Verapamil - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Choudhuri, S.K</creatorcontrib><creatorcontrib>Majumder, Surajit</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Choudhuri, S.K</au><au>Majumder, Surajit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Modulation of doxorubicin sensitivity by a novel organic compound, oxalyl bis ( N-phenyl) hydroxamic acid on acetyl aminofluorene-induced preneoplastic hepatocytes</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2003-12-08</date><risdate>2003</risdate><volume>202</volume><issue>1</issue><spage>25</spage><epage>34</epage><pages>25-34</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><coden>CALEDQ</coden><abstract>Development of biochemical modulators and application of the same with anticancer drugs is a current approach of modern cancer chemotherapy. We report the effect of two novel hydroxamic acid derivatives, viz. oxaly bis (
N-phenyl) hydroxamic acid (OBPHA) and succinyl bis (
N-phenyl) hydroxamic acid (SBPHA) on doxorubicin sensitivity and on P-glycoprotein (P-gp) in acetyl amino fluorene (AAF) induced preneoplastic hepatocytes in vitro. OBPHA increases doxorubicin sensitivity in AAF induced preneoplastic hepatocytes compared to normal hepatocytes. SBPHA, with an additional –CH
2–CH
2– group than OBPHA does not modulate the sensitivity of doxorubicin. The mechanism of action of OBPHA and SBPHA and their in vivo toxicity on male Swiss mice has been studied. OBPHA in combination with doxorubicin (i.e. OBPHA+doxorubicin) has higher antitumour activity compared to doxorubicin alone group; in consequence, OBPHA may decrease the dose related side effect of doxorubicin.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>14643023</pmid><doi>10.1016/S0304-3835(03)00474-9</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2003-12, Vol.202 (1), p.25-34 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_journals_1505365658 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | 2-Acetylaminofluorene - toxicity Acids Animals Antibiotics, Antineoplastic - therapeutic use Antineoplastic agents ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism Benzeneacetamides - therapeutic use Biological and medical sciences Bone marrow Calcium Channel Blockers - pharmacology Carcinogens Carcinogens - toxicity Cell Division - drug effects Dose-Response Relationship, Drug Doxorubicin (Dox) Doxorubicin - therapeutic use Drug dosages Drug Synergism Drug Therapy, Combination Experiments Glutathione - metabolism Hepatocytes - drug effects Hepatocytes - metabolism Hepatocytes - pathology Humans Hydroxamic Acids - therapeutic use Male Medical sciences Methods Mice Modulators Oxalates - therapeutic use Oxalyl bis ( N-phenyl) hydroxamic acid (OBPHA) Pharmacology. Drug treatments Precancerous Conditions - chemically induced Precancerous Conditions - drug therapy Precancerous Conditions - metabolism Rats Rats, Sprague-Dawley Rodents Sensitivity Spleen - metabolism Survival Rate Tumor Cells, Cultured Tumors Verapamil - pharmacology |
| title | Modulation of doxorubicin sensitivity by a novel organic compound, oxalyl bis ( N-phenyl) hydroxamic acid on acetyl aminofluorene-induced preneoplastic hepatocytes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T22%3A18%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Modulation%20of%20doxorubicin%20sensitivity%20by%20a%20novel%20organic%20compound,%20oxalyl%20bis%20(%20N-phenyl)%20hydroxamic%20acid%20on%20acetyl%20aminofluorene-induced%20preneoplastic%20hepatocytes&rft.jtitle=Cancer%20letters&rft.au=Choudhuri,%20S.K&rft.date=2003-12-08&rft.volume=202&rft.issue=1&rft.spage=25&rft.epage=34&rft.pages=25-34&rft.issn=0304-3835&rft.eissn=1872-7980&rft.coden=CALEDQ&rft_id=info:doi/10.1016/S0304-3835(03)00474-9&rft_dat=%3Cproquest_cross%3E3241505631%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1505365658&rft_id=info:pmid/14643023&rft_els_id=S0304383503004749&rfr_iscdi=true |